EGFR and non-small cell lung carcinoma: In spite of its increased adverse reactions particularly in the skin and gastrointestinal tract, the potent activity of DCB allowed for consideration of this effective therapy in EGFR-positive NSCLC.19–21 Proteins in the body can be modified by covalent binding to reactive metabolites that is regarded as the primary step in organ toxicities.22,23 In most cases, such reactive intermediates are produced through reactions of phase I metabolism.